Cargando…

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

The majority of breast cancers express the estrogen receptor (ER) and are dependent on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for these tumors. However, a superior outcome is achieved in a subset of ER positive (ER(+))/human epidermal growth factor rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorito, Nicla, Bacci, Marina, Smiriglia, Alfredo, Mannelli, Michele, Parri, Matteo, Comito, Giuseppina, Ippolito, Luigi, Giannoni, Elisa, Bonechi, Martina, Benelli, Matteo, Migliaccio, Ilenia, Malorni, Luca, Chiarugi, Paola, Morandi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140692/ https://www.ncbi.nlm.nih.gov/pubmed/32164162 http://dx.doi.org/10.3390/cells9030668

Ejemplares similares

Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer
por: Bacci, Marina, et al.
Publicado: (2019)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
por: Guarducci, Cristina, et al.
Publicado: (2018)

Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy
por: Ippolito, Luigi, et al.
Publicado: (2020)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma
por: Smiriglia, Alfredo, et al.
Publicado: (2023)

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
por: Malorni, Luca, et al.
Publicado: (2016)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors
por: Morandi, Andrea, et al.
Publicado: (2017)

Time-Dependent Stabilization of Hypoxia Inducible Factor-1α by Different Intracellular Sources of Reactive Oxygen Species
por: Calvani, Maura, et al.
Publicado: (2012)

Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches
por: Iozzo, Marta, et al.
Publicado: (2021)

Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts
por: Comito, Giuseppina, et al.
Publicado: (2016)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data
por: Romagnoli, Dario, et al.
Publicado: (2018)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

Nutritional Exchanges Within Tumor Microenvironment: Impact for Cancer Aggressiveness
por: Comito, Giuseppina, et al.
Publicado: (2020)

Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells
por: Taddei, Maria Letizia, et al.
Publicado: (2014)

Rac and Rho GTPases in cancer cell motility control
por: Parri, Matteo, et al.
Publicado: (2010)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Charting differentially methylated regions in cancer with Rocker-meth
por: Benelli, Matteo, et al.
Publicado: (2021)

Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread
por: Giannoni, Elisa, et al.
Publicado: (2015)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Globular Adiponectin as a Complete Mesoangioblast Regulator: Role in Proliferation, Survival, Motility, and Skeletal Muscle Differentiation
por: Fiaschi, Tania, et al.
Publicado: (2010)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
por: Galardi, Francesca, et al.
Publicado: (2020)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression
por: Pietrovito, Laura, et al.
Publicado: (2020)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vbq069uhmjram1f6g5f91t2332